Product Description
He aha ka Cannabidiphorol pauka?
ʻO Cannabidiol (CBDP) ka pauka he cannabinoid i ʻike ʻia i kekahi mau ʻano o ka mea kanu cannabis. Aia ia i ka papa like o nā pūhui e like me ka cannabinoids kaulana CBD (cannabidiol) a me THC (tetrahydrocannabinol). Ua like ka CBDP i ka molecular structure me ka cannabis compound THC a me CBD, akā ʻoi aku ka ikaika o 30 mau manawa. ʻOiai ua hana ʻia ka noiʻi liʻiliʻi ma CBDP, hōʻike ʻia ka noiʻi mua ʻana he mau waiwai therapeutic like me CBD, me nā pono kūpono no ka hopohopo, ke kaumaha, ka hōʻeha ʻeha, a me ka mumū.
ʻO ka noiʻi ma Cannabidiphorol (CBDP)
Ua alakaʻi kekahi pūʻulu ʻepekema Italia i ka haʻawina haʻihaʻi honua ma Cannabidiphorol (CBDP), a ua paʻi ʻia kā lākou hopena ma kahi pepa i kapa ʻia "He phytocannabinoid moʻolelo i hoʻokaʻawale ʻia mai Cannabis sativa L. me kahi hana cannabimimetic in vivo ʻoi aku ka kiʻekiʻe ma mua o 9-tetrahydrocannabinol: 9-Tetrahydrocannabiphorol” i loko o ka puke moʻolelo kaulana ʻo Scientific Reports i ka hopena o Dekemaba 2019. Ua hōʻike kēia haʻawina i kahi huli koʻikoʻi no ka mea ua hāʻawi ia i ka hoʻokolokolo piha mua o CBDP.
ʻO ka hiʻohiʻona o ka CBDP a me kāna mau pilina me nā cannabinoid receptors nā wahi nui o ke aʻo ʻana, me ka manaʻo kūikawā i ka 5-HT1A serotonin receptors, i ʻike ʻia e pāʻani i ke ʻano o ka manaʻo a me ka manaʻo hopohopo. Ua manaʻo ka poʻe noiʻi e like ka CBDP a me CBD, e hōʻike ana i nā hopena therapeutic e like me ka anti-stress, anti-depressant, a me nā ʻano anti-epileptic. Hoʻokumu ʻia kēia ma kā lākou ʻike mua.
Eia nō naʻe, he mea koʻikoʻi ia e hoʻomaopopo i ka noiʻi mua ʻana ma CBDP i kona wā kamaliʻi, a pono nā noiʻi hou e hoʻomaopopo piha i kona hopena pharmacological, nā noi therapeutic hiki, ka ʻike palekana, a me nā hopena ʻaoʻao.
ʻO nā pono o ka pauka Cannabidiphorol
Wahi a ka noiʻi i loaʻa i kēia manawa, ʻike ʻia ka CBDP i nā pono therapeutic like me CBD a hiki ke kōkua i nā maʻi e like me ke kaumaha, ke kaumaha, a me ka hopohopo. Eia hou, hiki i ka AASraw CBDP ke mālama i ka mumū, ka ʻeha, a me ka epilepsy.
- Hoʻopau i ka hopohopo, ke kaumaha, a me ke kaumaha
Hiki i ka CBDP ke hōʻemi i ke kaumaha, ka hopohopo, a me nā hōʻailona kaumaha. Hiki i ka CBDP ke hoʻololi i ka hana ʻana o nā mea loaʻa serotonin o ka lolo (5-HT1A) i nā pae serotonin kūlohelohe ma o ka hoʻāla ʻana i kēia mau mea loaʻa. ʻO ka "mole hauʻoli," serotonin, he mea nui ia no ka mālama ʻana i ka hopohopo a me ke ʻano. Wahi a nā haʻawina, hiki i ka CBD ke loaʻa i nā pono anti-stress a me nā anti-depressant ma o ka launa pū ʻana me nā mea hoʻokipa serotonin.
- Nā waiwai anti-epileptic
ʻO ka hopu ʻana a me ka hoʻopiʻi ʻole ʻia, kahi hōʻailona o ka epilepsy, lawe ʻia e ka hana uila aberrant i loko o ka lolo. Hoʻohana pinepine ʻia nā lāʻau anti-epileptic kahiko (AED) no ka mālama ʻana i ka hopu ʻana, akā ʻike paha kekahi poʻe ʻaʻole maikaʻi lākou a loaʻa nā hopena maikaʻi ʻole.
Manaʻo ʻia ʻo CBDP e launa pū me ka mea loaʻa 5-HT1A, he mea nui ia no ka mālama ʻana i ka hoʻokuʻu ʻana o nā neurotransmitters e like me ke serotonin i loko o ka lolo. He kuleana ko Serotonin i ka hoʻoponopono ʻana i ke ʻano, ka hopohopo, a me ka hana hopu, ma waena o nā kaʻina hana physiological.
Manaʻo kekahi mau noiʻi mua e hiki i nā cannabinoids, e like me CBD a me CBDP paha, ke hoʻomalu i ka hoʻokuʻu ʻana o ka neurotransmitter a hoʻopilikia i ka hauʻoli o nā neurons, a he hopena paha i ka hana hopu. Ma muli o kona hiki ke loaʻa i nā hopena anti-epileptic, ua huki nui ʻo CBD i ka noiʻi. ʻO ka hopena, ua ʻae ʻia kahi lāʻau lapaʻau CBD (Epidiolex) e mālama i nā ʻano kikoʻī o ka epilepsy.
Ke noiʻi nei nā mea noiʻi inā loaʻa i ka CBDP nā waiwai anti-epileptic i hāʻawi ʻia i nā ʻano like ʻole ma waena o CBD a me CBDP a me kā lākou launa pū ʻana me 5-HT1A receptors. Ma muli o kēia, hiki i ka CBDP ke lilo i mea hoʻohui waiwai i ka nui o nā lāʻau lapaʻau i loaʻa i nā poʻe me ka epilepsy, e hāʻawi ana i nā mea ʻē aʻe no ka mālama ʻana i ka hopu.
- Ka mālama ʻana i ka ʻeha a me ka mumū
Eia hou, hiki i ka CBDP ke kōkua i ka hōʻemi ʻana i ka ʻeha a me ka ʻeha. Hōʻike nā haʻawina he nui hiki i ka CBD ke mālama pono i nā hōʻailona o nā maʻi e like me ka fibromyalgia, ka sclerosis lehulehu, a me ka arthritis. Hāʻawi ʻia i ka CBDP a me CBD kaʻana like i nā mea like, he mea kūpono ke hoʻohālikelike ʻia e like ko lākou hopena.
He mea nui e hoʻomaopopo i ka noiʻi ʻana ma CBDP i kona wā mua, a pono nā noiʻi hou aʻe e hoʻomaopopo pono i kona mau pono kūpono a me nā hana o ka hana. Manaʻo ʻia ke kūkākūkā ʻana me nā limahana mālama ola kino a me nā loea ma ke kula no ka ʻike pololei loa a me nā manawa hou e pili ana i nā hopena a me ka hoʻohana ʻana o CBDP. Eia kekahi, he mea koʻikoʻi ke kūʻai ʻana i ka pauka cannabidiphorol (CBDP) mai kahi kumu hilinaʻi. ʻO AASraw, ma ke ʻano he cannabidiphorol (CBDP) ka mea hana a me ka mea hoʻolako, hiki ke hāʻawi i ka pauka cannabidiphorol maʻemaʻe ma lalo o ke kākoʻo o kahi kikowaena R&D kūʻokoʻa. He koho maikaʻi loa ia e kūʻai a kūʻai paha i ka pauka cannabidiphorol mai AASraw.
Ma hea e kūʻai ai i ka pauka Cannabidiphorol?
ʻO Cannabidiphorol (CBDP) ka pauka he cannabinoid hou a ʻimi ʻia i loaʻa i kekahi mau ʻano o ka cannabis. Ma muli o ka liʻiliʻi o ka loaʻa ʻana a me ka ʻike hou ʻana, ʻaʻole i loaʻa maʻamau ka CBDP e like me nā cannabinoids kaulana e like me THC a me CBD. No laila, pono e makaʻala i ka wā e noʻonoʻo ai i ke kūʻai ʻana i nā huahana CBDP, ʻoi aku ma ka pūnaewele.
KANAKA ke hāʻawi nei i ka pauka Cannabidiphorol maʻemaʻe, i hana ʻia ma lalo o nā kūlana mana koʻikoʻi e hōʻoia i ka maʻemaʻe a me ka ikaika. Hāʻawi ʻo AASraw i ka hoʻouna wikiwiki a me ka noʻonoʻo i nā mea kūʻai aku ma ka honua holoʻokoʻa, e maʻalahi ka loaʻa ʻana o nā huahana āu e makemake ai me ka wikiwiki a me ka maʻalahi.
Pehea e kūʻai ai i ka pauka Cannabidiphorol mai AASraw?
❶E hoʻokaʻaʻike mai iā mākou ma kā mākou ʻōnaehana nīnau leka uila, a i ʻole e waiho i kāu helu WhatsApp iā mākou, e hoʻopili aku kā mākou mea kūʻai aku (CSR) iā ʻoe i loko o 12 mau hola.
❷E hāʻawi iā mākou i kāu helu a me kāu helu wahi i nīnau ʻia.
❸Na kā mākou CRS e hāʻawi iā ʻoe i ka ʻōlelo ʻōlelo, ka manawa uku, ka helu huli, nā ala hoʻouna, a me ka lā i manaʻo ʻia e hiki mai ai (ETA).
❹E uku ʻia a hoʻouna ʻia nā waiwai i loko o 12 mau hola.
❺ Loaʻa nā waiwai a hāʻawi i nā manaʻo.
Mea kākau o kēia ʻatikala:
Kauka Monique Ua puka 'o Hong mai ke Kula Nui o UK Imperial College London Faculty of Medicine
Mea kākau moʻolelo puke moʻolelo ʻepekema:
1. Alexandra E. Golliher
Keʻena ʻOihana Kimia a me Biochemistry, New Mexico State University, United States
2. Pasquale Linciano
Ke Keʻena ʻEpekema Ola, Ke Kulanui o Modena a me Reggio Emilia, Modena, Italia
3. Fred Shahbazi
Keʻena ʻOihana Kimia a me Biochemistry, Ke Kulanui o Windsor, Kanada
4. Mohsen Hesami
Gosling Research Institute for Plant Preservation, Department of Plant Agriculture, University of Guelph, Canada
5. ʻO Jason Wallach
Keʻena ʻepekema ʻepekema, Philadelphia College of Pharmacy, University of the Science, Philadelphia, PA, United States
ʻAʻole ʻae kēia kauka/ ʻepekema i ke kūʻai, kūʻai ʻana, a hoʻohana paha i kēia huahana no kekahi kumu. ʻAʻohe pili a pili ʻole ʻo Aasraw, i hōʻike ʻia a i ʻole, me kēia kauka. ʻO ke kumu o ka haʻi ʻana i kēia kauka, ʻo ia ka hoʻomaikaʻi, hoʻomaikaʻi a hoʻomaikaʻi i ka hana noiʻi a me ka hoʻomohala piha i hana ʻia e nā ʻepekema e hana nei i kēia mea.
Reference
[1] Gaoni Y, Mechoulam R (1966). "Hashish - VII ʻO ka isomerization o cannabidiol i tetrahydrocannabinols". Tetrahedron. 22 (4): 1481–1488.
[2] Boggs DL, Nguyen JD, Morgenson D, Taffe MA, Ranganathan M (Ianuali 2018). "Nā hōʻike hōʻike a me ka preclinical no nā pilina hana o Cannabidiol a me Δ9-Tetrahydrocannabinol". Neuropsychopharmacology. 43 (1): 142–154.
[3] Citti C, Linciano P, Russo F, Luongo L, Iannotta M, Maione S, et al. (Kekemapa 2019). "He phytocannabinoid hou i hoʻokaʻawale ʻia mai Cannabis sativa L. me kahi hana cannabimimetic in vivo ʻoi aku ka kiʻekiʻe ma mua o Δ9-tetrahydrocannabinol: Δ9-Tetrahydrocannabiphorol". Nā Hōʻike ʻepekema. 9 (1): 20335.
[4] Marks MD, Tian L, Wenger JP, Omburo SN, Soto-Fuentes W, He J, et al. (2009). "Ka ʻike ʻana o nā genes moho e pili ana i ka biosynthesis Delta9-tetrahydrocannabinol ma Cannabis sativa". Nūpepa o ka hoʻokolohua Botany. 60 (13): 3715–3726.
[5] Adams R, Hunt M, Clark JH (1940). "Ka hoʻolālā o cannabidiol, kahi huahana i hoʻokaʻawale ʻia mai ka lāʻau marihuana o Minnesota wild hemp". Ka Nupepa o ka American Chemical Society. 62 (1): 196–200.
[6] Silva TB, Balbino CQ, Weiber AF (Mei 2015). "Ka pilina ma waena o cannabidiol a me psychosis: He loiloi". Nā moʻolelo o ka Psychiatry Clinical. 27 (2): 134–141.
[7] Bornheim LM, Kim KY, Li J, Perotti BY, Benet LZ (ʻAukake 1995). "Ka hopena o ka cannabidiol pretreatment ma nā kinetics o ka tetrahydrocannabinol metabolites i ka lolo ʻiole". ʻO ka Metabolism a me ka Disposition. 23 (8): 825–831.
[8] Verrico CD, Wesson S, Konduri V, Hofferek CJ, Vazquez-Perez J, Blair E, et al. (Sepatemaba 2020). "ʻO kahi haʻawina randomized, pālua-makapō, placebo-controlled o ka cannabidiol i kēlā me kēia lā no ka mālama ʻana i ka ʻeha osteoarthritis canine". ʻeha. 161 (9): 2191–2202.
[9] Maa E, Figi P (Iune 2014). "ʻO ka hihia no ka lāʻau lapaʻau i ka epilepsy". ʻEpilepsia. 55 (6): 783–786.
Mechoulam R, Peters M, Murillo-Rodriguez E, Hanus LO (ʻAukake 2007). "Cannabidiol - nā holomua hou". Kemika & Biodiversity (Nānā). 4 (8): 1678–1692.
E kiʻi i kahi hōʻaiʻē nui
